Inhibrx, Fresh Off $40M Funding to Advance Cancer Drugs, Eyes IPO

San Diego Biotechnology Network
San Diego Biotechnology Network
Inhibrx, Fresh Off $40M Funding to Advance Cancer Drugs, Eyes IPO
Loading
/

Two weeks after raising $40 million to push ahead with its drug development programs, Inhibrx submitted paperwork to the SEC revealing that it aims to raise money in the public market, too. The La Jolla, CA-based company, which is developing protein drugs targeting cancer and other diseases, was founded in 2010. Read more about the [?]